The drug works by blocking cellular transmission of the virus, thus preventing the disease.[11] It is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein.[4]
Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from
mpox and
rabbitpox and causes no serious side effects in humans.[6] Tecovirimat was first used for treatment in December 2018, after a laboratory-acquired
vaccinia virus infection.[12]
In the United States, tecovirimat is
indicated for the treatment of human smallpox disease.[4] In the European Union it is indicated for the treatment of smallpox, mpox, and cowpox.[5]
Mechanism of action
Tecovirimat inhibits the function of a major
envelope protein required for the production of extracellular virus. The drug prevents the virus from leaving an infected cell, hindering the spread of the virus within the body.[16]
Chemistry
The first synthesis of tecovirimat was published in a patent filed by scientists at
SIGA Technologies in 2004. It is made in two steps from
cycloheptatriene.[17]
As of 2009, the results of clinical trials support its use against smallpox and other related orthopoxviruses. It shows potential for a variety of uses including
preventive healthcare, as a post-exposure therapeutic, as a therapeutic, and an adjunct to vaccination.[21][failed verification]
Tecovirimat can be taken
by mouth and as of 2008, was permitted for
phase II trials by the U.S.
Food and Drug Administration (FDA). In
phase I trials, tecovirimat was generally well tolerated with no serious adverse events.[22] Due to its importance for
biodefense, the FDA designated tecovirimat for fast-track status, creating a path for expedited FDA review and eventual regulatory approval. On 13 July 2018, the FDA announced approval of tecovirimat for the treatment of smallpox.[23]
On 25 August 2022, the
AIDS Clinical Trials Group (ACTG) began a randomized, placebo-controlled, double-blinded trial on the safety and efficacy of tecovirimat for mpox, known as STOMP (Study of Tecovirimat for Human mpox Virus), aiming to enroll at least 500 participants with acute mpox infection.[24][25]
Society and culture
Legal status
In November 2021, the
Committee for Medicinal Products for Human Use of the
European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product tecovirimat SIGA, intended for the treatment of orthopoxvirus disease (smallpox, mpox,
cowpox, and
vaccinia complications) in adults and in children who weigh at least 13 kilograms (29 lb)[26] The applicant for this medicinal product is SIGA Technologies Netherlands B.V.[26] Tecovirimat was approved for medical use in the
European Union in January 2022.[5][27][28]
In December 2021,
Health Canada approved oral tecovirimat for the treatment of smallpox in people weighing at least 13 kilograms (29 lb).[1][29]
^
abc"Tecovirimat SIGA EPAR". European Medicines Agency. 10 November 2021.
Archived from the original on 16 May 2022. Retrieved 23 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^
abAU patent 2004249250, Bailey, Thomas R.; Jordan, Robert & Rippin, Susan R., "Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases", published 2004-12-29, assigned to SIGA Pharmaceuticals Inc
^Hughes DL (2019). "Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil". Organic Process Research & Development. 23 (7): 1298–1307.
doi:
10.1021/acs.oprd.9b00144.
S2CID197172102.
^
ab"Tecovirimat SIGA: Pending EC decision". European Medicines Agency. 11 November 2021.
Archived from the original on 13 November 2021. Retrieved 13 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.